With the rise of immunotherapy, combined treatment modalities targeting vascular endothelial growth factor and immune checkpoints offer new hope for improving the prognosis of metastatic RCC and high-risk limited RCC (4, 5). Here, VEGFA is linked to renal cell carcinoma.